Celcuity Inc. To Present at Upcoming Stifel and Jefferies Investor Conferences

Rhea-AI Summary

Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company focused on oncology targeted therapies, has announced upcoming presentations at two major investor conferences. CEO and Co-founder Brian Sullivan will participate in fireside chats at the Stifel 2024 Healthcare Conference on November 19 at 1:15 p.m. ET and the Jefferies London Healthcare Conference on November 21 at 11:30 a.m. GMT/6:30 a.m. ET. Both events will feature live webcasts and one-on-one investor meetings.

MINNEAPOLIS, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian Sullivan, Chief Executive Officer, and Co-founder of Celcuity, will present and be available for one-on-one investor meetings at the following investor conferences:

• A fireside chat at the Stifel 2024 Healthcare Conference at 1:15 p.m. ET on Tuesday, November 19, 2024. A live webcast will be available using this weblink: https://wsw.com/webcast/stifel96/celc/2061562; and
• A fireside chat at the Jefferies London Healthcare Conference at 11:30 a.m. GMT/6:30 a.m. ET on Thursday, November 21, 2024. A live webcast will be available using this weblink: https://wsw.com/webcast/jeff315/celc/1814988

About Celcuity 

Celcuity is a clinical-stage biotechnology company focused on development of targeted therapies for treatment of multiple solid tumor indications. The company's lead therapeutic candidate is gedatolisib, a potent, pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients. More detailed information about the VIKTORIA-1 study can be found at ClinicalTrials.gov . A Phase 1b/2 clinical trial, CELC-G-201, evaluating gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer, is enrolling patients. A Phase 3 clinical trial, VIKTORIA-2, evaluating gedatolisib plus a CDK4/6 inhibitor and fulvestrant as first-line treatment for patients with HR+/HER2- advanced breast cancer is expected to begin enrolling patients in the second quarter of 2025. Celcuity is headquartered in Minneapolis. Further information about Celcuity can be found at www.celcuity.com . Follow us on LinkedIn and Twitter .

Contacts: 
Celcuity Inc. 
Brian Sullivan, bsullivan@celcuity.com 
Vicky Hahne, vhahne@celcuity.com 
(763) 392-0123 

ICR Westwicke 
Maria Yonkoski, maria.yonkoski@westwicke.com   
(203) 682-7167

FAQ

When is Celcuity (CELC) presenting at the Stifel Healthcare Conference 2024?

Celcuity will present at the Stifel Healthcare Conference on Tuesday, November 19, 2024, at 1:15 p.m. ET.

What time is Celcuity's (CELC) presentation at the Jefferies London Healthcare Conference?

Celcuity will present at the Jefferies London Healthcare Conference on Thursday, November 21, 2024, at 11:30 a.m. GMT/6:30 a.m. ET.

Will Celcuity's (CELC) investor conference presentations be available via webcast?

Yes, both presentations will be available via live webcast, with specific weblinks provided for each conference.

Who will represent Celcuity (CELC) at the upcoming investor conferences?

Brian Sullivan, Chief Executive Officer and Co-founder of Celcuity, will represent the company at both conferences.